➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
Harvard Business School
Mallinckrodt
Merck

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 5,972,999

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,972,999
Title: Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
Abstract:This application relates to a pharmaceutical composition for the prevention and treatment of skin conditions in a patient having a sugar compound that is converted to a glycosaminoglycan in the patient in an amount sufficient to thicken the skin, a primary antioxidant component in an amount sufficient to substantially inhibit the formation of collagenase and elastase, at least one amino acid component in an amount sufficient to assist in the thickening of the skin, and at least one transition metal component in an amount effective to bind collagen and elastic fibers and rebuild skin. In one preferred form, the composition further includes a catechin-based preparation, a glucosamine or a pharmaceutically acceptable salt or ester thereof, and a chondroitin or a pharmaceutically acceptable salt or ester thereof. In a more preferred form, the invention further includes a vitamin E source, a cysteine source, a vitamin B.sub.3 source, quercetin dihydrate, pyridoxal 5 phosphate-Co B.sub.6, a methionine source, and a vitamin A source. The invention further relates to a method for the prevention or treatment of skin conditions by administering the pharmaceutical composition in an amount therapeutically effective to modify the thickness of the skin to prevent or treat at least one skin condition.
Inventor(s): Murad; Howard (Marina del Rey, CA)
Assignee:
Application Number:09/146,554
Patent Claims:see list of patent claims

Details for Patent 5,972,999

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial 2017-01-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Boehringer Ingelheim
McKinsey
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.